Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis
Non-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM). Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. This was a s...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/8/2163 |
| _version_ | 1827728866240626688 |
|---|---|
| author | Hiroshi Nomoto Yuka Takahashi Yoshinari Takano Hiroki Yokoyama Kazuhisa Tsuchida So Nagai Aika Miya Hiraku Kameda Kyu Yong Cho Akinobu Nakamura Tatsuya Atsumi |
| author_facet | Hiroshi Nomoto Yuka Takahashi Yoshinari Takano Hiroki Yokoyama Kazuhisa Tsuchida So Nagai Aika Miya Hiraku Kameda Kyu Yong Cho Akinobu Nakamura Tatsuya Atsumi |
| author_sort | Hiroshi Nomoto |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM). Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks. This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30]. In total, 58 participants met the criteria of this subanalysis. There were no statistical differences in baseline characteristics between the SWITCH (<i>n</i> = 31) and Continue groups (<i>n</i> = 27). FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (<i>p</i> < 0.01). The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (<i>p</i> = 0.016) and lower baseline FLI (<i>p</i> < 0.01). The multiple linear regression analysis revealed that the switch from dulaglutide was associated with an improvement in FLI (<i>p</i> = 0.041). Switching from conventional GLP-1RAs to once-weekly semaglutide might be beneficial for individuals with NAFLD complicated with T2DM. |
| first_indexed | 2024-03-10T23:38:56Z |
| format | Article |
| id | doaj.art-c2de1fab933e414497d9abc922114e1e |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T23:38:56Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-c2de1fab933e414497d9abc922114e1e2023-11-19T02:37:51ZengMDPI AGPharmaceutics1999-49232023-08-01158216310.3390/pharmaceutics15082163Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 SubanalysisHiroshi Nomoto0Yuka Takahashi1Yoshinari Takano2Hiroki Yokoyama3Kazuhisa Tsuchida4So Nagai5Aika Miya6Hiraku Kameda7Kyu Yong Cho8Akinobu Nakamura9Tatsuya Atsumi10Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, JapanDepartment of Diabetes and Endocrinology, Tonan Hospital, Sapporo 060-0004, Hokkaido, JapanJiyugaoka Medical Clinic, Obihiro 080-0016, Hokkaido, JapanManda Memorial Hospital, Sapporo 060-0062, Hokkaido, JapanDivision of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Centre, NTT East Corporation, Sapporo 060-0062, Hokkaido, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, JapanDepartment of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Hokkaido, JapanNon-alcoholic fatty liver disease (NAFLD) is an important common comorbidity in individuals with type 2 diabetes (T2DM). Although some glucagon-like peptide-1 receptor agonists (GLP-1RAs) have beneficial effects on NAFLD, the efficacy of once-weekly semaglutide has not been established. This was a subanalysis of the SWITCH-SEMA 1 study, a multicenter, prospective, randomized, parallel-group trial comparing switching from liraglutide or dulaglutide to once-weekly semaglutide in subjects with T2DM (SWITCH) versus continuing current GLP-1RAs (Continue) for 24 weeks. This subanalysis consisted of participants who were suspected to have NAFLD [fatty liver index (FLI) ≥ 30]. In total, 58 participants met the criteria of this subanalysis. There were no statistical differences in baseline characteristics between the SWITCH (<i>n</i> = 31) and Continue groups (<i>n</i> = 27). FLI significantly improved during treatment in the SWITCH group (68.6 to 62.7) but not in the Continue group (71.1 to 72.3) (<i>p</i> < 0.01). The improvement of FLI in the SWITCH group was greater in switching from dulaglutide to semaglutide and significantly correlated with older age (<i>p</i> = 0.016) and lower baseline FLI (<i>p</i> < 0.01). The multiple linear regression analysis revealed that the switch from dulaglutide was associated with an improvement in FLI (<i>p</i> = 0.041). Switching from conventional GLP-1RAs to once-weekly semaglutide might be beneficial for individuals with NAFLD complicated with T2DM.https://www.mdpi.com/1999-4923/15/8/2163fatty liverglucagon-like receptor agonistsonce-weekly semaglutidetype 2 diabetes |
| spellingShingle | Hiroshi Nomoto Yuka Takahashi Yoshinari Takano Hiroki Yokoyama Kazuhisa Tsuchida So Nagai Aika Miya Hiraku Kameda Kyu Yong Cho Akinobu Nakamura Tatsuya Atsumi Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis Pharmaceutics fatty liver glucagon-like receptor agonists once-weekly semaglutide type 2 diabetes |
| title | Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis |
| title_full | Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis |
| title_fullStr | Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis |
| title_full_unstemmed | Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis |
| title_short | Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis |
| title_sort | effect of switching to once weekly semaglutide on non alcoholic fatty liver disease the switch sema 1 subanalysis |
| topic | fatty liver glucagon-like receptor agonists once-weekly semaglutide type 2 diabetes |
| url | https://www.mdpi.com/1999-4923/15/8/2163 |
| work_keys_str_mv | AT hiroshinomoto effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT yukatakahashi effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT yoshinaritakano effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT hirokiyokoyama effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT kazuhisatsuchida effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT sonagai effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT aikamiya effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT hirakukameda effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT kyuyongcho effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT akinobunakamura effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis AT tatsuyaatsumi effectofswitchingtoonceweeklysemaglutideonnonalcoholicfattyliverdiseasetheswitchsema1subanalysis |